Common ADRs of erenumab include which of the following?

Prepare for the Pharmacology IV – Headache Therapeutics Test. Review the therapeutic approaches, tackle multiple-choice questions with explanations, and boost your test-taking confidence. Ace your exam with precision!

Multiple Choice

Common ADRs of erenumab include which of the following?

Erenumab blocks the CGRP pathway, and this can lead to a range of common adverse effects. Injection-site reactions are frequent with any subcutaneous biologic, since the administration itself often causes local irritation or redness. CGRP plays a role in gut motility, so inhibiting its signaling can slow intestinal movement, resulting in constipation, which is a well-recognized adverse event with CGRP inhibitors. CGRP also acts as a vasodilator, so blocking its activity can modestly affect vascular tone and blood pressure in some patients, with hypertension reported in the safety data. Because injection-site reactions, constipation, and hypertension have all been observed with erenumab, all of these are considered common adverse effects.

Erenumab blocks the CGRP pathway, and this can lead to a range of common adverse effects. Injection-site reactions are frequent with any subcutaneous biologic, since the administration itself often causes local irritation or redness. CGRP plays a role in gut motility, so inhibiting its signaling can slow intestinal movement, resulting in constipation, which is a well-recognized adverse event with CGRP inhibitors. CGRP also acts as a vasodilator, so blocking its activity can modestly affect vascular tone and blood pressure in some patients, with hypertension reported in the safety data. Because injection-site reactions, constipation, and hypertension have all been observed with erenumab, all of these are considered common adverse effects.

More practice questions